Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus EC chemotherapy with or without thoracic radiotherapy for first-line extensive-stage small cell lung cancer
ChiCTR2400085580Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Jun 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adebrelimab, etoposide and carboplatin in small cell lung cancer (SCLC) (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Progression-free survival. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
adebrelimabetoposidecarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400085580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085580.